Loading…

Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study

The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and sev...

Full description

Saved in:
Bibliographic Details
Published in:Physiological genomics 2024-05, Vol.56 (5), p.409-416
Main Authors: Eriksson, Mikael, Lipcsey, Miklós, Ilboudo, Yann, Yoshiji, Satoshi, Richards, Brent, Hultström, Michael
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233
container_end_page 416
container_issue 5
container_start_page 409
container_title Physiological genomics
container_volume 56
creator Eriksson, Mikael
Lipcsey, Miklós
Ilboudo, Yann
Yoshiji, Satoshi
Richards, Brent
Hultström, Michael
description The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03), = 0.698, and OR 0.95 (0.91-1.00), = 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16), = 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37), = 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14), = 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39), = 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01), = 0.23, and OR 1.05 (0.99-1.12), = 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity. The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia.
doi_str_mv 10.1152/physiolgenomics.00145.2023
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_DiVA_org_uu_530452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3056793994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233</originalsourceid><addsrcrecordid>eNpdkU1P3DAQhq0KVCjtX6giuPTQbP0Z29wQbQEJ1Eu3V8tJJtQosYMdFy2_Hm8XOCCN5Dk8M_NaD0LHBK8IEfTb_HeTXBhvwYfJdWmFMeFiRTFl79AhEYzUlDZyr_RY81oxTg7Qh5TutpxU4j06YIo1WjfyEK3XMUyhz6PzVakEc3Kpsr4v7T-IUM0e8hS8s6eVrZaHUCc7zSNUN-B7GJ31VSx0CfJoFxfKhiX3m49of7Bjgk_P7xFa__zx-_yyvv51cXV-dl13jMql7jRn0HNM8NAKOmjStFY1yko5YGGFKPE7zJUarJI9AcXbAcumAy55Iwhl7Ah93e1NDzDn1szRTTZuTLDOfHd_zkyItyZnIxjmghb8yw6fY7jPkBYzudTBOFoPISdDNVVCcSF4QU_eoHchR18-YxgWjdRM6y11uqO6GFKKMLwmINhsXZk3rsx_V2brqgx_fj6R2wn619EXOewJejeVIA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3056793994</pqid></control><display><type>article</type><title>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</title><source>American Physiological Society:Jisc Collections:American Physiological Society Journals ‘Read Publish &amp; Join’ Agreement:2023-2024 (Reading list)</source><creator>Eriksson, Mikael ; Lipcsey, Miklós ; Ilboudo, Yann ; Yoshiji, Satoshi ; Richards, Brent ; Hultström, Michael</creator><creatorcontrib>Eriksson, Mikael ; Lipcsey, Miklós ; Ilboudo, Yann ; Yoshiji, Satoshi ; Richards, Brent ; Hultström, Michael</creatorcontrib><description>The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03), = 0.698, and OR 0.95 (0.91-1.00), = 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16), = 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37), = 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14), = 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39), = 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01), = 0.23, and OR 1.05 (0.99-1.12), = 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity. The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia.</description><identifier>ISSN: 1094-8341</identifier><identifier>ISSN: 1531-2267</identifier><identifier>EISSN: 1531-2267</identifier><identifier>DOI: 10.1152/physiolgenomics.00145.2023</identifier><identifier>PMID: 38369967</identifier><language>eng</language><publisher>United States: American Physiological Society</publisher><subject>acute kidney injury ; critical care ; Mendelian randomization ; Mortality ; Pneumonia ; Sepsis ; Single-nucleotide polymorphism ; uromodulin</subject><ispartof>Physiological genomics, 2024-05, Vol.56 (5), p.409-416</ispartof><rights>Copyright American Physiological Society May 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233</cites><orcidid>0000-0003-4675-1099 ; 0000-0003-4013-1446</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38369967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-530452$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Eriksson, Mikael</creatorcontrib><creatorcontrib>Lipcsey, Miklós</creatorcontrib><creatorcontrib>Ilboudo, Yann</creatorcontrib><creatorcontrib>Yoshiji, Satoshi</creatorcontrib><creatorcontrib>Richards, Brent</creatorcontrib><creatorcontrib>Hultström, Michael</creatorcontrib><title>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</title><title>Physiological genomics</title><addtitle>Physiol Genomics</addtitle><description>The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03), = 0.698, and OR 0.95 (0.91-1.00), = 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16), = 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37), = 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14), = 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39), = 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01), = 0.23, and OR 1.05 (0.99-1.12), = 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity. The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia.</description><subject>acute kidney injury</subject><subject>critical care</subject><subject>Mendelian randomization</subject><subject>Mortality</subject><subject>Pneumonia</subject><subject>Sepsis</subject><subject>Single-nucleotide polymorphism</subject><subject>uromodulin</subject><issn>1094-8341</issn><issn>1531-2267</issn><issn>1531-2267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkU1P3DAQhq0KVCjtX6giuPTQbP0Z29wQbQEJ1Eu3V8tJJtQosYMdFy2_Hm8XOCCN5Dk8M_NaD0LHBK8IEfTb_HeTXBhvwYfJdWmFMeFiRTFl79AhEYzUlDZyr_RY81oxTg7Qh5TutpxU4j06YIo1WjfyEK3XMUyhz6PzVakEc3Kpsr4v7T-IUM0e8hS8s6eVrZaHUCc7zSNUN-B7GJ31VSx0CfJoFxfKhiX3m49of7Bjgk_P7xFa__zx-_yyvv51cXV-dl13jMql7jRn0HNM8NAKOmjStFY1yko5YGGFKPE7zJUarJI9AcXbAcumAy55Iwhl7Ah93e1NDzDn1szRTTZuTLDOfHd_zkyItyZnIxjmghb8yw6fY7jPkBYzudTBOFoPISdDNVVCcSF4QU_eoHchR18-YxgWjdRM6y11uqO6GFKKMLwmINhsXZk3rsx_V2brqgx_fj6R2wn619EXOewJejeVIA</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Eriksson, Mikael</creator><creator>Lipcsey, Miklós</creator><creator>Ilboudo, Yann</creator><creator>Yoshiji, Satoshi</creator><creator>Richards, Brent</creator><creator>Hultström, Michael</creator><general>American Physiological Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope><orcidid>https://orcid.org/0000-0003-4675-1099</orcidid><orcidid>https://orcid.org/0000-0003-4013-1446</orcidid></search><sort><creationdate>20240501</creationdate><title>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</title><author>Eriksson, Mikael ; Lipcsey, Miklós ; Ilboudo, Yann ; Yoshiji, Satoshi ; Richards, Brent ; Hultström, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>acute kidney injury</topic><topic>critical care</topic><topic>Mendelian randomization</topic><topic>Mortality</topic><topic>Pneumonia</topic><topic>Sepsis</topic><topic>Single-nucleotide polymorphism</topic><topic>uromodulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eriksson, Mikael</creatorcontrib><creatorcontrib>Lipcsey, Miklós</creatorcontrib><creatorcontrib>Ilboudo, Yann</creatorcontrib><creatorcontrib>Yoshiji, Satoshi</creatorcontrib><creatorcontrib>Richards, Brent</creatorcontrib><creatorcontrib>Hultström, Michael</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>Physiological genomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eriksson, Mikael</au><au>Lipcsey, Miklós</au><au>Ilboudo, Yann</au><au>Yoshiji, Satoshi</au><au>Richards, Brent</au><au>Hultström, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study</atitle><jtitle>Physiological genomics</jtitle><addtitle>Physiol Genomics</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>56</volume><issue>5</issue><spage>409</spage><epage>416</epage><pages>409-416</pages><issn>1094-8341</issn><issn>1531-2267</issn><eissn>1531-2267</eissn><abstract>The outcome for patients with sepsis-associated acute kidney injury in the intensive care unit (ICU) remains poor. Low serum uromodulin (sUMOD) protein levels have been proposed as a causal mediator of this effect. We investigated the effect of different levels of sUMOD on the risk of sepsis and severe pneumonia and outcomes in these conditions. A two-sample Mendelian randomization (MR) study was performed. Single-nucleotide polymorphisms (SNPs) associated with increased levels of sUMOD were identified and used as instrumental variables for association with outcomes. Data from different cohorts were combined based on disease severity and meta-analyzed. Five SNPs associated with increased sUMOD levels were identified and tested in six datasets from two biobanks. There was no protective effect of increased levels of sUMOD on the risk of sepsis [two cohorts, odds ratio (OR) 0.99 (95% confidence interval 0.95-1.03), = 0.698, and OR 0.95 (0.91-1.00), = 0.060, respectively], risk of sepsis requiring ICU admission [OR 1.04 (0.93-1.16), = 0.467], ICU mortality in sepsis [OR 1.00 (0.74-1.37), = 0.987], risk of pneumonia requiring ICU admission [OR 1.05 (0.98-1.14), = 0.181], or ICU mortality in pneumonia [OR 1.17 (0.98-1.39), = 0.079]. Meta-analysis of hospital-admitted and ICU-admitted patients separately yielded similar results [OR 0.98 (0.95-1.01), = 0.23, and OR 1.05 (0.99-1.12), = 0.86, respectively]. Among patients with sepsis and severe pneumonia, there was no protective effect of different levels of sUMOD. Results were consistent regardless of geographic origins and not modified by disease severity. The presence of acute kidney injury in severe infections increases the likelihood of poor outcome severalfold. A decrease in serum uromodulin (sUMOD), synthetized in the kidney, has been proposed as a mediator of this effect. Using the Mendelian randomization technique, we tested the hypothesis that increased sUMOD is protective in severe infections. Analyses, however, showed no evidence of a protective effect of higher levels of sUMOD in sepsis or severe pneumonia.</abstract><cop>United States</cop><pub>American Physiological Society</pub><pmid>38369967</pmid><doi>10.1152/physiolgenomics.00145.2023</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4675-1099</orcidid><orcidid>https://orcid.org/0000-0003-4013-1446</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1094-8341
ispartof Physiological genomics, 2024-05, Vol.56 (5), p.409-416
issn 1094-8341
1531-2267
1531-2267
language eng
recordid cdi_swepub_primary_oai_DiVA_org_uu_530452
source American Physiological Society:Jisc Collections:American Physiological Society Journals ‘Read Publish & Join’ Agreement:2023-2024 (Reading list)
subjects acute kidney injury
critical care
Mendelian randomization
Mortality
Pneumonia
Sepsis
Single-nucleotide polymorphism
uromodulin
title Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A58%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Uromodulin%20in%20sepsis%20and%20severe%20pneumonia:%20a%20two-sample%20Mendelian%20randomization%20study&rft.jtitle=Physiological%20genomics&rft.au=Eriksson,%20Mikael&rft.date=2024-05-01&rft.volume=56&rft.issue=5&rft.spage=409&rft.epage=416&rft.pages=409-416&rft.issn=1094-8341&rft.eissn=1531-2267&rft_id=info:doi/10.1152/physiolgenomics.00145.2023&rft_dat=%3Cproquest_swepu%3E3056793994%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c327t-c943ed4010fb52f916ba868a77f05a55094c0488fa87d1e84bf076ce474651233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3056793994&rft_id=info:pmid/38369967&rfr_iscdi=true